Avanzarx is a discoverer and developer of highly desired therapeutic assets designed exclusively for established pharmaceutical companies to acquire. We utilize investment capital to advanced in-licensed technologies we hand select based on our many years of experience and expertise in the pharmaceutical industry. We develop these assets from pre-clinical stage into early clinical stage assets (Phase-I or Phase-II) and these are sold/licensed to established pharma who would complete the pivotal trials and commercialize the asset. Terms of the transaction are upfront cash, milestone payments and royalties on commercial sales. Our model is built to return capital back to investors in under 5 years with a high IRR. We structured the company to function under a "Program Centric Liquidity Thesis". Each program becomes its own Delaware C-Corp subsidiary of the parent HoldCo (a Delaware LLC). Investors can invest in the top company (LLC) or can invest in the individual program C-Corps. When a program is acquired by an established pharmaceutical company, proceeds and multiples on invested capital (MOIC) are returned to investors and the company proceeds are sent to the Hold Co and used to fund a new program centric subsidiary, thereby growing the overall company further. The LLC allows for advantaged tax treatment and improves our ability to return more capital to the growth of the company.